Balaxi Pharmaceuticals Limited (IN:BALAXI)
:BALAXI
Want to see IN:BALAXI full AI Analyst Report?
BALAXI Stock Chart & Stats
₹27.06
-₹2.28(-2.93%)
At close: 4:00 PM EST
₹27.06
-₹2.28(-2.93%)
Day’s Range― - ―
52-Week Range₹15.20 - ₹54.70
Previous CloseN/A
Volume27.88K
Average Volume (3M)75.37K
Market Cap
₹1.26B
Enterprise Value₹722.70M
Total Cash (Recent Filing)₹388.49M
Total Debt (Recent Filing)₹565.23M
Price to Earnings (P/E)89.8
Beta1.14
Next Earnings
Jul 30, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.62
Shares Outstanding55,207,500
10 Day Avg. Volume158,740
30 Day Avg. Volume75,367
Financial Highlights & Ratios
PEG Ratio-0.64
Price to Book (P/B)0.34
Price to Sales (P/S)0.31
P/FCF Ratio-1.89
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Moderate Leverage / Strong Equity BaseA low debt-to-equity (~0.23) and an expanded equity base provide a durable financial cushion. This moderates refinancing and solvency risk, giving management room to restructure operations or fund growth without immediate distress financing, supporting multi-month strategic flexibility.
Healthy Gross MarginsSustained gross margins near 42% indicate core product economics remain strong. That suggests structural pricing power or low direct costs; if operating expenses are managed, the business can restore operating profitability and convert margins into durable cash generation over several quarters.
Diversified Distribution-led Business ModelA marketing, distribution and export model creates multiple revenue channels across domestic and international markets. This capital-light structure supports scalable growth, diversifies geographic demand risk, and enables reliance on commercial reach rather than heavy fixed-asset investment.
Bears Say
Persistent Negative Operating And Free Cash FlowTwo consecutive years of negative operating and free cash flow indicate the business is consuming cash despite reported earnings. This recurring cash burn raises structural funding risk, limits reinvestment, and may force external financing or asset sales, constraining long-term strategic options.
Sharp Collapse In Profitability And ROEA steep drop in net margin and ROE to near-zero reflects material deterioration in earnings quality and returns on capital. Sustained weak profitability undermines internal capital generation, reduces ability to fund growth from operations, and weakens competitive positioning over the medium term.
Choppy, Downtrending Revenue TrajectoryRevenue volatility and a slip below prior-year levels point to inconsistent demand or market share pressures. This top-line instability complicates margin recovery, capital planning, and long-term forecasting, increasing execution risk for any multi-quarter turnaround plan.
Balaxi Pharmaceuticals Limited News
BALAXI FAQ
What was Balaxi Pharmaceuticals Limited’s price range in the past 12 months?
Balaxi Pharmaceuticals Limited lowest stock price was ₹15.20 and its highest was ₹54.70 in the past 12 months.
What is Balaxi Pharmaceuticals Limited’s market cap?
Balaxi Pharmaceuticals Limited’s market cap is ₹1.26B.
When is Balaxi Pharmaceuticals Limited’s upcoming earnings report date?
Balaxi Pharmaceuticals Limited’s upcoming earnings report date is Jul 30, 2026 which is in 45 days.
How were Balaxi Pharmaceuticals Limited’s earnings last quarter?
Balaxi Pharmaceuticals Limited released its earnings results on May 28, 2026. The company reported ₹0.11 earnings per share for the quarter, beating the consensus estimate of N/A by ₹0.11.
Is Balaxi Pharmaceuticals Limited overvalued?
According to Wall Street analysts Balaxi Pharmaceuticals Limited’s price is currently Overvalued.
Does Balaxi Pharmaceuticals Limited pay dividends?
Balaxi Pharmaceuticals Limited pays a Notavailable dividend of ₹0.5 which represents an annual dividend yield of N/A. See more information on Balaxi Pharmaceuticals Limited dividends here
What is Balaxi Pharmaceuticals Limited’s EPS estimate?
Balaxi Pharmaceuticals Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Balaxi Pharmaceuticals Limited have?
Balaxi Pharmaceuticals Limited has 55,207,500 shares outstanding.
What happened to Balaxi Pharmaceuticals Limited’s price movement after its last earnings report?
Balaxi Pharmaceuticals Limited reported an EPS of ₹0.11 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Balaxi Pharmaceuticals Limited?
Currently, no hedge funds are holding shares in IN:BALAXI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Balaxi Pharmaceuticals Limited
Balaxi Pharmaceuticals Limited, through its entity Balaxi Ventures Ltd., primarily operates as an international wholesale distributor specializing in pharmaceuticals, various food items, and hardware supplies. The company's corporate base is situated in Hyderabad, Telangana. Its extensive product range features pharmaceutical formulations, a variety of food products, and construction-related hardware. Notably, both its pharmaceutical and builders' hardware offerings are manufactured under contract at different plants located across India. Within its food segment, the firm markets a selection of food and biscuit products under the recognizable brand name YAP. Balaxi Global DMCC is among the key subsidiaries within the company's structure.
Technical Analysis
Biofil Chemicals & Pharmaceuticals Ltd.
―
Gkb Ophthalmics Limited
―
―
Lasa Supergenerics Ltd.
―
Vivimed Labs Limited
―